FR3091818B1 - formulation pour le traitement des symptômes liés au sevrage tabagique ou de psychotropes - Google Patents

formulation pour le traitement des symptômes liés au sevrage tabagique ou de psychotropes Download PDF

Info

Publication number
FR3091818B1
FR3091818B1 FR1900425A FR1900425A FR3091818B1 FR 3091818 B1 FR3091818 B1 FR 3091818B1 FR 1900425 A FR1900425 A FR 1900425A FR 1900425 A FR1900425 A FR 1900425A FR 3091818 B1 FR3091818 B1 FR 3091818B1
Authority
FR
France
Prior art keywords
formulation
treatment
smoking cessation
symptoms related
psychotropic drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1900425A
Other languages
English (en)
Other versions
FR3091818A1 (fr
Inventor
Robert Aboudaram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CEMAPS, CH
Original Assignee
Edelweiss Laboratory SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edelweiss Laboratory SA filed Critical Edelweiss Laboratory SA
Priority to FR1900425A priority Critical patent/FR3091818B1/fr
Priority to PCT/EP2020/051168 priority patent/WO2020148443A1/fr
Priority to EP20700613.1A priority patent/EP3911412A1/fr
Priority to CN202080017050.4A priority patent/CN113543850A/zh
Priority to US17/423,086 priority patent/US20220079982A1/en
Publication of FR3091818A1 publication Critical patent/FR3091818A1/fr
Application granted granted Critical
Publication of FR3091818B1 publication Critical patent/FR3091818B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L’invention concerne une formulation homéopathique préparée à partir des six souches homéopathiques tabacum, Nux vomica, Aurum metallicum, Passiflora incarnata, Agnus castus et Lobelia inflata, ladite formulation homéopathique ayant des effets bénéfiques sur les personnes en sevrage tabagique ou de psychotropes. Figure à publier avec l’abrégé : [-]
FR1900425A 2019-01-17 2019-01-17 formulation pour le traitement des symptômes liés au sevrage tabagique ou de psychotropes Active FR3091818B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1900425A FR3091818B1 (fr) 2019-01-17 2019-01-17 formulation pour le traitement des symptômes liés au sevrage tabagique ou de psychotropes
PCT/EP2020/051168 WO2020148443A1 (fr) 2019-01-17 2020-01-17 Formulation pour le traitement des symptomes lies au sevrage tabagique ou de psychotropes
EP20700613.1A EP3911412A1 (fr) 2019-01-17 2020-01-17 Formulation pour le traitement des symptomes lies au sevrage tabagique ou de psychotropes
CN202080017050.4A CN113543850A (zh) 2019-01-17 2020-01-17 用于治疗吸烟戒断或精神药物戒断相关症状的制剂
US17/423,086 US20220079982A1 (en) 2019-01-17 2020-01-17 Formulation for treating tobacco or psychotrope withdrawal symptoms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1900425A FR3091818B1 (fr) 2019-01-17 2019-01-17 formulation pour le traitement des symptômes liés au sevrage tabagique ou de psychotropes
FR1900425 2019-01-17

Publications (2)

Publication Number Publication Date
FR3091818A1 FR3091818A1 (fr) 2020-07-24
FR3091818B1 true FR3091818B1 (fr) 2021-04-16

Family

ID=66867396

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1900425A Active FR3091818B1 (fr) 2019-01-17 2019-01-17 formulation pour le traitement des symptômes liés au sevrage tabagique ou de psychotropes

Country Status (5)

Country Link
US (1) US20220079982A1 (fr)
EP (1) EP3911412A1 (fr)
CN (1) CN113543850A (fr)
FR (1) FR3091818B1 (fr)
WO (1) WO2020148443A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105062A1 (en) * 2004-11-12 2006-05-18 Mccleary Edward L Composition and method for modulating addictive behaviors
US20050100513A1 (en) * 2003-11-10 2005-05-12 Watkins Mary B. Homeopathic method and system for treating nicotine addiction
RU2541167C2 (ru) * 2013-03-29 2015-02-10 Александр Николаевич Куршев Способ лечения аддикции
US20170106039A1 (en) * 2014-03-14 2017-04-20 Louise GUTOWSKI Anti-addictive composition
DE202014103195U1 (de) * 2014-07-11 2014-07-23 Marianna Gross Vorrichtung zum Applizieren von Flüssigkeiten
DE202014103194U1 (de) * 2014-07-11 2014-07-29 Marianna Gross Homöopathisches Mittel zur Raucherentwöhnung

Also Published As

Publication number Publication date
US20220079982A1 (en) 2022-03-17
WO2020148443A1 (fr) 2020-07-23
FR3091818A1 (fr) 2020-07-24
CN113543850A (zh) 2021-10-22
EP3911412A1 (fr) 2021-11-24

Similar Documents

Publication Publication Date Title
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
CN105878613A (zh) 痹痛灵外用酊剂及其制备方法
FR3091818B1 (fr) formulation pour le traitement des symptômes liés au sevrage tabagique ou de psychotropes
Panossian et al. Adaptogens in psychiatric practice
MX2022001153A (es) Regimen de dosificacion y administracion para el tratamiento o prevencion de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab.
Lee et al. Do treatment strategies of fremanezumab have similar effect on migraine?
Watson Should we be complimentary about complementary therapies?
AR109760A1 (es) Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson
Li History and Story on Chinese Buddhist Doctor from Poetry of the Tang
CN105326937A (zh) 用于治疗风湿性心脏病的中药组合物
AR102494A1 (es) Métodos para tratar enfermedades oculares
Dash et al. Effects of pushpadhanwa rasa on psychological imbalances in polycystic ovarian disease patients and its management
Gürok et al. Facial Edema Developed After Use of Olanzapine: A Case Report
Ortega Nanometric and vectorized gold as a potential strategy towards Treatment of Rheumatoid Arthritis
CN106581244A (zh) 一种治疗脚癣的中药配方
Bai et al. Effect of Electroacupuncture on Behavior and Key Factors of CaMK signaling Pathway in Depressed Rats
Aliaev et al. Treatment of chronic prostatitis in prophylaxis of prostatic adenoma
CN105497223A (zh) 一种治疗咳嗽的中药组合物
Gomez Garcia Anaphylaxis in an elderly patient: case report
Kh et al. THE POTENTIAL OF ENDOPHYTIC FUNGI OF MEDICINAL PLANTS OF UZBEKISTAN IN ANTICOAGULANT THERAPY
MA47053A1 (fr) Utilisation d'anticorps anti-c1s dans la fabrication d'un medicament destiné au traitement de maladies et de troubles a mediation par le complément.
眭明红 Mechanism of electroacupuncture on “Zusanli (ST 36)” for chemotherapy-induced peripheral neuropathy
Samadzadeh et al. Efficacy of Diltiazem Plus Tolterodine in Treatment Of Overactive Bladder after Prostatectomy
Sagar Methotrexate/leflunomide
Lutgen Artemisia Plants: A Deadly Weapon Against Tropical Diseases

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200724

PLFP Fee payment

Year of fee payment: 3

CA Change of address

Effective date: 20211206

RM Correction of a material error

Effective date: 20211206

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

TP Transmission of property

Owner name: CEMAPS, CH

Effective date: 20230809